CP-751,871 MK0646 BIIB022 AMG479 R1507 Linsitinib (OSI-906) XL228 Cixutumumab (IMC-A12) MEDI-573

Figitumumab (CP-751,871)

Figitumumab (earlier called CP-751,871) is an inhibitor of IGF-1R in clinical trials.

Manufacturer and website link:  Pfizer  http://pfizer.com/home/

oral or intravenous: Intravenous

Description from NCI Drug Dictionary: Figitumumab or CP-751871 is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. CP-751871 selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival.

Ongoing Trials:  Trials which could potentially enroll  a GIST patient are listed below:

Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

There are additional numerous trials, both Phase I AND phase II,  of this drug for other cancers (lung, breast, prostate, and colorectal).